Modern Healthcare Technology Holdings Limited(0919.HK)
No price history available.
Key financial summary
Financials in HKD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | HKDm | 431 | 356 | 406 | 455 | 453 | 443 | N/A | N/A |
| Operating profit | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | HKDm | 126 | -69 | -21 | -10 | -5 | -2 | N/A | N/A |
| EPS reported | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in HKD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Modern Healthcare Technology Holdings Limited, an investment holding company, provides beauty and wellness services in Hong Kong, Mainland China, Singapore, and Australia. The company operates in two segments, Beauty and Wellness Services, and Skincare and Wellness Products. It offers beauty and facial services; aesthetics services, such as skincare treatment, professional consultation, skin care and anti-ageing, and referral services on plastic reconstruction; slimming services, including weight management programs; spa and massage services comprising resplendent bathroom furnishings and a hydrotherapeutic pool, as well as foot spa, and foot treatment and massage services; and haircare and removal, make-up, joint and intimate care, and body check and genetic test services. The company also sells skincare and wellness products under the be, FERRECARE, p.e.n, Y.U.E., Advanced Natural, Malu Wilz, Byotea, Care Plus, Mu-lan Spa, Cellnoc, Veribel, Castille, Dr Plus, IconX, Eclat du teint, and Natural Care brand names. In addition, it provides sub-franchising services in relation to beautification and gymnastic services; beauty and wellness treatment training program; property holding services; food and beverage services; fund management services; advertising services; maid agency services; licensing services; and management services, as well as holds property leases. The company was formerly known as Modern Beauty Salon Holdings Limited and changed its name to Modern Healthcare Technology Holdings Limited. The company was incorporated in 2005 and is headquartered in Kowloon Bay, Hong Kong.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Modern Healthcare Technology Holdings Limited (0919.HK)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Modern Healthcare Technology Holdings Limited, an investment holding company, provides beauty and wellness services in Hong Kong, Mainland China, Singapore, and Australia. The company operates in two segments, Beauty and Wellness Services, and Skincare and Wellness Products. It offers beauty and facial services; aesthetics services, such as skincare treatment, professional consultation, skin care and anti-ageing, and referral services on plastic reconstruction; slimming services, including weight management programs; spa and massage services comprising resplendent bathroom furnishings and a hydrotherapeutic pool, as well as foot spa, and foot treatment and massage services; and haircare and removal, make-up, joint and intimate care, and body check and genetic test services. The company also sells skincare and wellness products under the be, FERRECARE, p.e.n, Y.U.E., Advanced Natural, Malu Wilz, Byotea, Care Plus, Mu-lan Spa, Cellnoc, Veribel, Castille, Dr Plus, IconX, Eclat du teint, and Natural Care brand names. In addition, it provides sub-franchising services in relation to beautification and gymnastic services; beauty and wellness treatment training program; property holding services; food and beverage services; fund management services; advertising services; maid agency services; licensing services; and management services, as well as holds property leases. The company was formerly known as Modern Beauty Salon Holdings Limited and changed its name to Modern Healthcare Technology Holdings Limited. The company was incorporated in 2005 and is headquartered in Kowloon Bay, Hong Kong.